S'abonner

The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis - 25/07/16

Doi : 10.1016/j.amjmed.2016.03.007 
Giovanni Corona, MD, PhD a, 1, Corinna Giuliani, MD b, 1, Gabriele Parenti, MD, PhD c, 1, Giorgio L. Colombo, MSc d, Alessandra Sforza, MD a, Mario Maggi, MD, PhD e, Gianni Forti, MD b, Alessandro Peri, MD, PhD b,
a Endocrinology Unit, Maggiore-Bellaria Hospital, Bologna, Italy 
b Endocrine Unit, “Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders for the Development of Novel Therapies” (DENOThe), Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi Hospital, Italy 
c Department of Medicine and Geriatrics, Careggi Hospital, Italy 
d Department of Drug Sciences, University of Pavia, Italy 
e Andrology Unit, “Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders for the Development of Novel Therapies” (DENOThe), Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Careggi Hospital, Italy 

Requests for reprints should be addressed to Alessandro Peri, MD, PhD, Endocrine Unit, Department of Experimental and Clinical Biomedical Sciences, “Mario Serio”, University of Florence, Viale Pieraccini, 6, Florence 50139, Italy.Endocrine Unit, Department of Experimental and Clinical Biomedical Sciences“Mario Serio”, University of FlorenceViale Pieraccini, 6Florence50139Italy

Abstract

Background

Hyponatremia is the most common electrolyte abnormality observed in clinical practice. Several studies have demonstrated that hyponatremia is associated with an increased length of hospital stay and of hospital resource utilization. To clarify the impact of hyponatremia on the length of hospitalization and costs, we performed a meta-analysis based on published studies that compared hospital length of stay and cost between patients with and without hyponatremia.

Methods

An extensive Medline, Embase, and Cochrane search was performed to retrieve all studies published up to April 1, 2015 using the following words: “hyponatremia” or “hyponatraemia” AND “hospitalization” or “hospitalisation.” A meta-analysis was performed including all studies comparing duration of hospitalization and hospital readmission rate in subjects with and without hyponatremia.

Results

Of 444 retrieved articles, 46 studies satisfied the inclusion criteria, encompassing a total of 3,940,042 patients; among these, 757,763 (19.2%) were hyponatremic. Across all studies, hyponatremia was associated with a significantly longer duration of hospitalization (3.30 [2.90-3.71; 95% CIs] mean days; P < .000). Similar results were obtained when patients with associated morbidities were analyzed separately. Furthermore, hyponatremic patients had a higher risk of readmission after the first hospitalization (odds ratio 1.32 [1.18-1.48; 95% CIs]; P < .000). A meta-regression analysis showed that the hyponatremia-related length of hospital stay was higher in males (Slope = 0.09 [0.05-0.12; 95% CIs]; P = .000 and Intercept = −1.36 [−3.03-0.32; 95% CIs]; P = .11) and in elderly patients (Slope = 0.002 [0.001-0.003; 95% CIs]; P < .000 and Intercept = 0.89 [0.83-0.97; 95% CIs]; P < .001). A negative association between serum [Na+] cutoff and duration of hospitalization was detected. No association between duration of hospitalization, serum [Na+], and associated morbidities was observed. Finally, when only US studies (n = 8) were considered, hyponatremia was associated with up to around $3000 higher hospital costs/patient when compared with the cost of normonatremic subjects.

Conclusions

This meta-analysis confirms that hyponatremia is associated with a prolonged hospital length of stay and higher risk of readmission. These observations suggest that hyponatremia may represent one important determinant of the hospitalization costs.

Le texte complet de cet article est disponible en PDF.

Keywords : Costs, Hospitalization, Hyponatremia


Plan


 Funding: None.
 Conflict of Interest: AP has served as a consultant and member of advisory boards for Otsuka. GLC has served as a consultant on advisory boards for Astellas, LEO Pharma, Sanofi, Merck Sharp and Dohme, DOC Generici, Takeda, UCB Pharma, and MerckSerono, and has received research and educational grants from Bayer HealthCare, Takeda, Gilead Sciences, Merck Sharp and Dohme, Otsuka and LEO Pharma. The authors report no other conflicts of interest in this work.
 Authorship: All authors had access to the data. Study concept and design: GC; Acquisition of data: CG, GP; Analysis and interpretation of data: GC, AP, GLC; Drafting of the manuscript: GC, AP, CG; Critical revision of the manuscript for important intellectual content: GF, MM, AS, GLC; Statistical analysis: GC; Study supervision: AP.


© 2016  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 129 - N° 8

P. 823 - août 2016 Retour au numéro
Article précédent Article précédent
  • Trapped Among the Waves: Massive Jejunojejunal Intussusception After Gastric Bypass
  • Rohan Mandaliya, Divya Aggarwal, Philip Lim
| Article suivant Article suivant
  • Impact of Hyponatremia Correction on the Risk for 30-Day Readmission and Death in Patients with Congestive Heart Failure
  • Jacques D. Donzé, Patrick E. Beeler, David W. Bates

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.